Illumina launches scientific research testing products jointly developed with Merck & Co.

36氪 was informed that Immena announced the launch of a scientific research testing product jointly developed with Merck & Co. According to reports, the new detection product introduces Myriad Genetics’ proven HRD technology into Illumina’s TruSight™ Oncology 500, enabling a single, comprehensive pan-cancer detection that can identify key mutations that have an important impact on the occurrence and development of cancer.

Post a Comment